1Restore
DynamX Bioadaptor matched the acute performance of Resolute Onyx DES
DynamX vs. Resolute Onyx
Device and Lesion Success Rates
99.6% DynamX
vs 99.6% Resolute Onyx
The future of vascular intervention won’t just evolve,
it will adapt.
From the landmark BIOADAPTOR RCT trial
The first device with RCT data demonstrating significantly better effectiveness in early RETURN of vessel function and stabilization of plaques vs. state-of-the-art drug-eluting stent (DES)
0
1
2
3
4
5
6
7
8
9.0
1
2
3
4
5
6
7
8
9%
1
2
3
4
5
6
7
8
9.0
1
2
3
4
5
6
7
8
9%
Primary endpoint: target lesion failure at 12 months vs. 2.8% for Resolute Onyx™
(p < 0.001)
0
1
2
3
4
5
6
7
8
90
1
2
3
4
5
6
7
8
9%
1
2
3
4
5
6
7
8
90
1
2
3
4
5
6
7
8
9%
Increase in blood flow with every heartbeat, as pulsatility returns
-0
1
2
3
4
5
6
7
8
9%
1
2
3
4
5
6
7
8
9%
Plaque volume regression in lipid rich lesions vs. +10% for DES
(p = 0.008)
The Transformation
BIOADAPTOR RCT Investigators
Shigeru Saito, MD
Department of Cardiology, Iryohojin Tokushukai Shonan Kamakura General Hospital, Kamakura City, Japan
Holger Nef, MD, PhD
Department of Cardiology and Angiology, University of Giessen, Giessen, Germany
Stefan Verheye, MD, PhD
Interventional Cardiology, ZNA Cardiovascular Center Middelheim, Antwerp, Belgium
Mark Webster, MD
Cardiac Investigation Unit, Auckland City Hospital, Auckland, New Zealand
